Elizabeth Cairns
Senior Biopharma Reporter at Endpoints News
Senior biopharma journalist at Endpoints News
Articles
-
1 week ago |
endpoints.news | Elizabeth Cairns
Scholar Rock’s muscle-building antibody helped patients who are overweight or obese preserve lean mass when they were taking Eli Lilly’s incretin drug Zepbound, the biotech … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
1 week ago |
endpoints.news | Elizabeth Cairns
Mineralys Therapeutics said Tuesday that its blood pressure med lorundrostat has succeeded in a Phase 2 trial in subjects with hypertension and comorbid chronic kidney … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
1 week ago |
endpoints.news | Elizabeth Cairns
Immuneering’s oral MEK inhibitor allowed 94% of pancreatic cancer patients in a Phase 2a trial to survive six months when used first line in combination … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
1 week ago |
endpoints.news | Elizabeth Cairns
Eli Lilly’s under-the-radar amylin analog allowed obese patients in a Phase 1 trial to lose up to 11.3% of their bodyweight. The drug appears to … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
2 weeks ago |
endpoints.news | Elizabeth Cairns |Kyle LaHucik
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric. Last month, Morgan Stanley … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 807
- DMs Open
- No
Summit says PD-1xVEGF bispecific ivonsecimab misses overall survival in closely-watched lung cancer study $SMMT https://t.co/S5j0rvKDbv
RT @endpts: Live today at 3 p.m. ET: Is biotech sentiment really as bad as it seems? Join Endpoints' @JohnCendpts, @ArmstrongDrew, and @ky_…
RT @ArmstrongDrew: 🎙️Let's talk "most favored nation"! Today on Post-Hoc Live, I'll be joined by biotech lobbyist Nick Shipley to unpack t…
